Gemcitabine delivered by fucoidan/chitosan nanoparticles presents increased toxicity over human breast cancer cells
To produce marine-origin nanoparticles (NPs) aiming to develop more effective and tolerated therapies for breast cancer. NPs based in two marine-origin polymers (fucoidan and chitosan) were prepared by polyelectrolyte complexation, for the delivery of an antitumor drug model (gemcitabine [Gem]). Fin...
Saved in:
| Published in | Nanomedicine (London, England) Vol. 13; no. 16; pp. 2037 - 2050 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Future Medicine Ltd
01.08.2018
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | To produce marine-origin nanoparticles (NPs) aiming to develop more effective and tolerated therapies for breast cancer.
NPs based in two marine-origin polymers (fucoidan and chitosan) were prepared by polyelectrolyte complexation, for the delivery of an antitumor drug model (gemcitabine [Gem]).
Final formulation resulted in stable NPs around 115-140 nm in size and with a polydispersity index less than 0.2. Gem was encapsulated at a maximum entrapment efficiency of 35-42%. Drug-release studies demonstrated that around 84% of Gem is released within 4 h. Cytotoxicity results of Gem-loaded NPs showed increased toxicity (around 25%) when compared with free Gem.
The drug-loaded NPs present increased toxicity over human breast cancer cells without increasing toxic effects over endothelial cells. |
|---|---|
| AbstractList | To produce marine-origin nanoparticles (NPs) aiming to develop more effective and tolerated therapies for breast cancer.AIMTo produce marine-origin nanoparticles (NPs) aiming to develop more effective and tolerated therapies for breast cancer.NPs based in two marine-origin polymers (fucoidan and chitosan) were prepared by polyelectrolyte complexation, for the delivery of an antitumor drug model (gemcitabine [Gem]).MATERIALS & METHODSNPs based in two marine-origin polymers (fucoidan and chitosan) were prepared by polyelectrolyte complexation, for the delivery of an antitumor drug model (gemcitabine [Gem]).Final formulation resulted in stable NPs around 115-140 nm in size and with a polydispersity index less than 0.2. Gem was encapsulated at a maximum entrapment efficiency of 35-42%. Drug-release studies demonstrated that around 84% of Gem is released within 4 h. Cytotoxicity results of Gem-loaded NPs showed increased toxicity (around 25%) when compared with free Gem.RESULTSFinal formulation resulted in stable NPs around 115-140 nm in size and with a polydispersity index less than 0.2. Gem was encapsulated at a maximum entrapment efficiency of 35-42%. Drug-release studies demonstrated that around 84% of Gem is released within 4 h. Cytotoxicity results of Gem-loaded NPs showed increased toxicity (around 25%) when compared with free Gem.The drug-loaded NPs present increased toxicity over human breast cancer cells without increasing toxic effects over endothelial cells.CONCLUSIONThe drug-loaded NPs present increased toxicity over human breast cancer cells without increasing toxic effects over endothelial cells. To produce marine-origin nanoparticles (NPs) aiming to develop more effective and tolerated therapies for breast cancer. NPs based in two marine-origin polymers (fucoidan and chitosan) were prepared by polyelectrolyte complexation, for the delivery of an antitumor drug model (gemcitabine [Gem]). Final formulation resulted in stable NPs around 115-140 nm in size and with a polydispersity index less than 0.2. Gem was encapsulated at a maximum entrapment efficiency of 35-42%. Drug-release studies demonstrated that around 84% of Gem is released within 4 h. Cytotoxicity results of Gem-loaded NPs showed increased toxicity (around 25%) when compared with free Gem. The drug-loaded NPs present increased toxicity over human breast cancer cells without increasing toxic effects over endothelial cells. To produce marine-origin nanoparticles (NPs) aiming to develop more effective and tolerated therapies for breast cancer. NPs based in two marine-origin polymers (fucoidan and chitosan) were prepared by polyelectrolyte complexation, for the delivery of an antitumor drug model (gemcitabine [Gem]). Final formulation resulted in stable NPs around 115-140 nm in size and with a polydispersity index less than 0.2. Gem was encapsulated at a maximum entrapment efficiency of 35-42%. Drug-release studies demonstrated that around 84% of Gem is released within 4 h. Cytotoxicity results of Gem-loaded NPs showed increased toxicity (around 25%) when compared with free Gem. The drug-loaded NPs present increased toxicity over human breast cancer cells without increasing toxic effects over endothelial cells. Aim: To produce marine-origin nanoparticles (NPs) aiming to develop more effective and tolerated therapies for breast cancer. Materials & methods: NPs based in two marine-origin polymers (fucoidan and chitosan) were prepared by polyelectrolyte complexation, for the delivery of an antitumor drug model (gemcitabine [Gem]). Results: Final formulation resulted in stable NPs around 115–140 nm in size and with a polydispersity index less than 0.2. Gem was encapsulated at a maximum entrapment efficiency of 35–42%. Drug-release studies demonstrated that around 84% of Gem is released within 4 h. Cytotoxicity results of Gem-loaded NPs showed increased toxicity (around 25%) when compared with free Gem. Conclusion: The drug-loaded NPs present increased toxicity over human breast cancer cells without increasing toxic effects over endothelial cells. |
| Author | Silva, Tiago H Reis, Rui L Oliveira, Catarina Neves, Nuno M Martins, Albino |
| AuthorAffiliation | 2ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal 3The Discoveries Centre for Regenerative & Precision Medicine, Headquarters at University of Minho, Avepark, 4805-017 Barco, Guimarães, Portugal 13B's Research Group - Biomaterials, Biodegradables & Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering & Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, 4805-017 Barco, Guimarães, Portugal |
| AuthorAffiliation_xml | – name: 13B's Research Group - Biomaterials, Biodegradables & Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering & Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, 4805-017 Barco, Guimarães, Portugal – name: 2ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal – name: 3The Discoveries Centre for Regenerative & Precision Medicine, Headquarters at University of Minho, Avepark, 4805-017 Barco, Guimarães, Portugal |
| Author_xml | – sequence: 1 givenname: Catarina surname: Oliveira fullname: Oliveira, Catarina – sequence: 2 givenname: Nuno M surname: Neves fullname: Neves, Nuno M – sequence: 3 givenname: Rui L surname: Reis fullname: Reis, Rui L – sequence: 4 givenname: Albino surname: Martins fullname: Martins, Albino – sequence: 5 givenname: Tiago H surname: Silva fullname: Silva, Tiago H |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30189774$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kb1r3TAUxUVIyVczZi2CLl2c6Mu2NJaQpoVAl3YWsnxNFGzpVZJL33-f675kCWSSdPU7h8s55-Q4pgiEXHF2LQTvb2JcGsG4bhhj6oic8V7ppjOdPP5_l02rtTkl56U8MdZqwdkJOZUoMH2vzki5h8WH6oYQgY4wh7-QYaTDnk6rT2F08cY_hpqKizS6mHYu1-BnKHSXoUCshYboM7iCqpr-BTTb04Qu9HFdUDRsf5V6Fz3OPMxz-Ug-TG4ucPlyXpDf3-5-3X5vHn7e_7j9-tB4JdvaaFCt88Y5z3rDmBM9KN9NWnUggPPBaCUmqYUyrQEH0Pay4x2KtBgmNUp5Qb4cfHc5_VmhVLuEsm3gIqS1WMyCi15KwRD9_AZ9SmuOuJ0VEmNmigmO1KcXah0WGO0uh8XlvX2NEwF5AHxOpWSY7JZtDSnW7MJsObNbaRZLs1tpdisNVc0b1avxe7w58NNaV2zBB8Bw7eGFe2EHEd7RPgNuu61a |
| CitedBy_id | crossref_primary_10_2217_nnm_2021_0175 crossref_primary_10_4103_jcrt_jcrt_1583_22 crossref_primary_10_1016_j_ijbiomac_2019_11_191 crossref_primary_10_2174_1567201820666230112170035 crossref_primary_10_1016_j_jddst_2022_103580 crossref_primary_10_2174_0929867326666181213093718 crossref_primary_10_3390_app13031883 crossref_primary_10_1016_j_ijbiomac_2021_12_130 crossref_primary_10_1088_1361_6528_abd3cb crossref_primary_10_2174_157489281703220610170559 crossref_primary_10_1016_j_carbpol_2023_121555 crossref_primary_10_1155_2022_8006642 crossref_primary_10_2147_IJN_S485861 crossref_primary_10_1016_j_ijpharm_2021_120548 crossref_primary_10_3390_polym13244400 crossref_primary_10_1016_j_algal_2019_101748 crossref_primary_10_1016_j_ijpharm_2020_120043 crossref_primary_10_1016_j_carbpol_2020_116131 crossref_primary_10_1016_j_drudis_2023_103851 crossref_primary_10_1016_j_ijbiomac_2025_139936 crossref_primary_10_2217_nnm_2022_0206 crossref_primary_10_1016_j_ijbiomac_2019_12_177 crossref_primary_10_1016_j_ijbiomac_2025_140144 crossref_primary_10_1039_D0FO03153D crossref_primary_10_2139_ssrn_4074425 crossref_primary_10_1007_s13346_022_01144_3 crossref_primary_10_1021_acsapm_1c01102 crossref_primary_10_1016_j_carres_2024_109271 crossref_primary_10_1016_j_foodres_2021_110522 crossref_primary_10_2174_1381612828666220422091611 crossref_primary_10_3390_cancers12123776 crossref_primary_10_3390_ijms231911821 crossref_primary_10_3390_ijms24032615 crossref_primary_10_1016_j_carbpol_2023_120972 crossref_primary_10_1080_02652048_2025_2474457 crossref_primary_10_2217_nnm_2018_0455 crossref_primary_10_1016_j_drudis_2025_104315 crossref_primary_10_2174_1381612828666220211153931 crossref_primary_10_3390_md17120654 crossref_primary_10_1007_s13346_023_01329_4 crossref_primary_10_1016_j_jddst_2023_104228 crossref_primary_10_1016_j_ijbiomac_2020_10_091 crossref_primary_10_1016_j_ijbiomac_2022_07_068 crossref_primary_10_3389_fmars_2021_723333 |
| Cites_doi | 10.2147/DDDT.S143047 10.1016/j.carbpol.2017.02.065 10.1016/j.msec.2015.11.067 10.1016/B978-0-12-407821-5.00005-X 10.1016/j.colsurfb.2016.06.010 10.1016/j.jbiosc.2015.05.006 10.1201/b15636 10.1002/mabi.201600340 10.2217/nnm-2017-0055 10.3816/CBC.2004.s.002 10.3322/caac.21208 10.1007/978-3-319-23422-9_7 10.2217/nnm-2017-0228 10.3322/caac.21203 10.1016/j.addr.2008.09.001 10.1016/j.colsurfb.2016.05.023 10.1007/s11051-008-9446-4 10.1517/17425247.2012.652614 10.3390/ma10030291 10.3390/md11114267 10.1179/1743280412Y.0000000002 10.1016/j.ejphar.2016.05.016 10.3390/polym8020030 10.1186/1757-2215-7-38 10.2147/IJN.S149306 10.1002/term.1752 10.4137/CMO.S6252 10.1634/theoncologist.2017-0472 10.2217/nnm-2016-0095 10.3390/md13095920 10.3390/md14080145 10.1159/000069315 10.1007/978-0-85729-787-7_2 10.1007/s11095-010-0073-2 10.3390/md12084379 10.1186/s11671-016-1698-9 10.1007/s10965-014-0415-6 10.1016/0003-2697(86)90176-4 10.1016/j.ijpharm.2012.08.008 10.3390/md13042327 |
| ContentType | Journal Article |
| Copyright | 2018 Future Medicine Ltd Copyright Future Medicine Ltd Aug 2018 |
| Copyright_xml | – notice: 2018 Future Medicine Ltd – notice: Copyright Future Medicine Ltd Aug 2018 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU EHMNL FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.2217/nnm-2018-0004 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College UK & Ireland Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library UK & Ireland Database ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest One Academic Middle East (New) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering |
| EISSN | 1748-6963 |
| EndPage | 2050 |
| ExternalDocumentID | 30189774 10_2217_nnm_2018_0004 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United Kingdom--UK United States--US |
| GeographicLocations_xml | – name: United Kingdom--UK – name: United States--US |
| GroupedDBID | - 0R 123 29M 34G 39C 3V. 53G 70G 7X7 88E 8AO 8FI 8FJ ABUWG ACGFS AENEX AFKRA AHMBA ALMA_UNASSIGNED_HOLDINGS BBAFP BENPR BPHCQ BVXVI CS3 DU5 EBS EHMNL EJD F5P FYUFA H13 HZ IAO IEA IHR INH INR M1P MV1 NTCAX O9- P2P PQQKQ PRINS PSQYO RFM --- 0R~ 4.4 AAWFG AAYXX ABJNI ACGFO ACWKX ADBBV AFFYO ALIPV CCPQU CITATION FD6 HMCUK HZ~ ITC M4Z OVD PHGZM PHGZT PROAC RPM TDBHL TEORI TFL TFMDE TMEDX UKHRP ~ZZ CGR CUY CVF ECM EIF NPM 7XB 8FK ABNDM K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 |
| ID | FETCH-LOGICAL-c435t-8e45ac9aac07900a27e4c6f846e2e11b9842f3824959eaee573616e4582bf4d33 |
| IEDL.DBID | 7X7 |
| ISSN | 1743-5889 1748-6963 |
| IngestDate | Fri Jul 11 16:43:30 EDT 2025 Fri Jul 25 05:50:20 EDT 2025 Thu Apr 03 07:02:11 EDT 2025 Thu Apr 24 22:59:13 EDT 2025 Tue Jul 01 04:06:07 EDT 2025 Tue Jan 05 21:59:13 EST 2021 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 16 |
| Keywords | breast cancer cells chitosan endothelial cells nanoparticles drug-delivery system gemcitabine fucoidan polyelectrolyte complexation |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c435t-8e45ac9aac07900a27e4c6f846e2e11b9842f3824959eaee573616e4582bf4d33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://hdl.handle.net/1822/58734 |
| PMID | 30189774 |
| PQID | 2321704021 |
| PQPubID | 54598 |
| PageCount | 14 |
| ParticipantIDs | proquest_miscellaneous_2101273320 proquest_journals_2321704021 pubmed_primary_30189774 crossref_citationtrail_10_2217_nnm_2018_0004 crossref_primary_10_2217_nnm_2018_0004 futurescience_futuremedicine_10_2217_nnm_2018_0004 |
| ProviderPackageCode | RFM NTCAX 70G CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-08-01 |
| PublicationDateYYYYMMDD | 2018-08-01 |
| PublicationDate_xml | – month: 08 year: 2018 text: 2018-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Nanomedicine (London, England) |
| PublicationTitleAlternate | Nanomedicine (Lond) |
| PublicationYear | 2018 |
| Publisher | Future Medicine Ltd |
| Publisher_xml | – name: Future Medicine Ltd |
| References | e_1_3_3_18_1 e_1_3_3_17_1 e_1_3_3_39_1 e_1_3_3_19_1 e_1_3_3_14_1 e_1_3_3_37_1 e_1_3_3_13_1 e_1_3_3_38_1 e_1_3_3_16_1 e_1_3_3_35_1 e_1_3_3_15_1 e_1_3_3_36_1 e_1_3_3_10_1 e_1_3_3_33_1 e_1_3_3_34_1 e_1_3_3_12_1 e_1_3_3_31_1 e_1_3_3_11_1 e_1_3_3_32_1 Kim S-K (e_1_3_3_30_1) 2013 e_1_3_3_40_1 e_1_3_3_41_1 Smith M (e_1_3_3_26_1) 2017; 6 e_1_3_3_7_1 e_1_3_3_6_1 e_1_3_3_9_1 e_1_3_3_8_1 e_1_3_3_29_1 Hortobagyi GN (e_1_3_3_24_1) 2001; 15 e_1_3_3_28_1 e_1_3_3_25_1 Hertel LW (e_1_3_3_21_1) 1990; 50 e_1_3_3_27_1 e_1_3_3_3_1 e_1_3_3_44_1 e_1_3_3_20_1 e_1_3_3_45_1 e_1_3_3_5_1 e_1_3_3_23_1 e_1_3_3_42_1 e_1_3_3_4_1 e_1_3_3_22_1 e_1_3_3_43_1 |
| References_xml | – volume: 15 start-page: 15 issue: 2 year: 2001 ident: e_1_3_3_24_1 article-title: Treatment of advanced breast cancer with gemcitabine and vinorelbine publication-title: Oncology (Williston Park) – ident: e_1_3_3_40_1 doi: 10.2147/DDDT.S143047 – ident: e_1_3_3_12_1 doi: 10.1016/j.carbpol.2017.02.065 – ident: e_1_3_3_17_1 doi: 10.1016/j.msec.2015.11.067 – ident: e_1_3_3_32_1 doi: 10.1016/B978-0-12-407821-5.00005-X – ident: e_1_3_3_45_1 doi: 10.1016/j.colsurfb.2016.06.010 – ident: e_1_3_3_29_1 doi: 10.1016/j.jbiosc.2015.05.006 – start-page: 527 volume-title: Chitin and Derivatives: Advances in Drug Discovery and Developments year: 2013 ident: e_1_3_3_30_1 doi: 10.1201/b15636 – ident: e_1_3_3_10_1 doi: 10.1002/mabi.201600340 – ident: e_1_3_3_38_1 doi: 10.2217/nnm-2017-0055 – ident: e_1_3_3_22_1 doi: 10.3816/CBC.2004.s.002 – ident: e_1_3_3_3_1 doi: 10.3322/caac.21208 – ident: e_1_3_3_6_1 doi: 10.1007/978-3-319-23422-9_7 – ident: e_1_3_3_42_1 doi: 10.2217/nnm-2017-0228 – ident: e_1_3_3_4_1 doi: 10.3322/caac.21203 – ident: e_1_3_3_16_1 doi: 10.1016/j.addr.2008.09.001 – ident: e_1_3_3_44_1 doi: 10.1016/j.colsurfb.2016.05.023 – ident: e_1_3_3_33_1 doi: 10.1007/s11051-008-9446-4 – ident: e_1_3_3_27_1 doi: 10.1517/17425247.2012.652614 – ident: e_1_3_3_36_1 doi: 10.3390/ma10030291 – ident: e_1_3_3_37_1 doi: 10.3390/md11114267 – ident: e_1_3_3_7_1 doi: 10.1179/1743280412Y.0000000002 – ident: e_1_3_3_39_1 doi: 10.1016/j.ejphar.2016.05.016 – ident: e_1_3_3_28_1 doi: 10.3390/polym8020030 – volume: 6 start-page: 125 issue: 4 year: 2017 ident: e_1_3_3_26_1 article-title: Controlled release of targeted anti-leukemia drugs azacitidine and decitabine monitored using surface-enhanced Raman scattering (SERS) spectroscopy publication-title: Med. J. Chem. – ident: e_1_3_3_19_1 doi: 10.1186/1757-2215-7-38 – ident: e_1_3_3_25_1 doi: 10.2147/IJN.S149306 – volume: 50 start-page: 4417 issue: 14 year: 1990 ident: e_1_3_3_21_1 article-title: Evaluation of the antitumor activity of gemcitabine (2’,2’-difluoro-2’-deoxycytidine) publication-title: Cancer Res. – ident: e_1_3_3_13_1 doi: 10.1002/term.1752 – ident: e_1_3_3_18_1 doi: 10.4137/CMO.S6252 – ident: e_1_3_3_20_1 doi: 10.1634/theoncologist.2017-0472 – ident: e_1_3_3_41_1 doi: 10.2217/nnm-2016-0095 – ident: e_1_3_3_9_1 doi: 10.3390/md13095920 – ident: e_1_3_3_11_1 doi: 10.3390/md14080145 – ident: e_1_3_3_23_1 doi: 10.1159/000069315 – ident: e_1_3_3_5_1 doi: 10.1007/978-0-85729-787-7_2 – ident: e_1_3_3_34_1 doi: 10.1007/s11095-010-0073-2 – ident: e_1_3_3_15_1 doi: 10.3390/md12084379 – ident: e_1_3_3_43_1 doi: 10.1186/s11671-016-1698-9 – ident: e_1_3_3_14_1 doi: 10.1007/s10965-014-0415-6 – ident: e_1_3_3_31_1 doi: 10.1016/0003-2697(86)90176-4 – ident: e_1_3_3_35_1 doi: 10.1016/j.ijpharm.2012.08.008 – ident: e_1_3_3_8_1 doi: 10.3390/md13042327 |
| SSID | ssj0058210 |
| Score | 2.4190085 |
| Snippet | To produce marine-origin nanoparticles (NPs) aiming to develop more effective and tolerated therapies for breast cancer.
NPs based in two marine-origin... Aim: To produce marine-origin nanoparticles (NPs) aiming to develop more effective and tolerated therapies for breast cancer. Materials & methods: NPs based in... To produce marine-origin nanoparticles (NPs) aiming to develop more effective and tolerated therapies for breast cancer.AIMTo produce marine-origin... |
| SourceID | proquest pubmed crossref futurescience |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2037 |
| SubjectTerms | Antineoplastic Agents - administration & dosage Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Breast cancer breast cancer cells Breast Neoplasms - metabolism Cancer therapies Cell Line Cell Line, Tumor Cell Survival - drug effects chitosan Chitosan - chemistry Cytotoxicity Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - chemistry Deoxycytidine - pharmacology Drug delivery systems Drug Delivery Systems - methods drug-delivery system Drugs endothelial cells Endothelial Cells - drug effects fucoidan gemcitabine Humans Microscopy, Electron, Scanning Microscopy, Electron, Transmission Nanoparticles Nanoparticles - chemistry Nanoparticles - ultrastructure polyelectrolyte complexation Polymers Polymers - chemistry Polysaccharides - chemistry |
| Title | Gemcitabine delivered by fucoidan/chitosan nanoparticles presents increased toxicity over human breast cancer cells |
| URI | http://dx.doi.org/10.2217/nnm-2018-0004 https://www.ncbi.nlm.nih.gov/pubmed/30189774 https://www.proquest.com/docview/2321704021 https://www.proquest.com/docview/2101273320 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA9696Ic4ue5eh4RxCfLtkmbpk-isuci3iLiwb6VaTqFhbt0vXbh7r93ps2u3sP6VEqTUDK_zEfmS4h3RjtLmkASNUnuohSzNIIKamKGmCog-WwN5w6fL8z8Iv22zJbhwq0LYZVbnjgw6rp1fEc-Jcmf5IQ4lXxc_464axR7V0MLjfvikEuXMarz5c7g4hzQkBCpo8zaYqyxqWihqfdXBJDEDlnVd2TS0VjMIwig_YrnIIDOHotHQXOUn0ZSPxH30D8VD_-pJ_hMdF_xypGxT9YuyhovOeYCa1ndymbj2lUNfspug7YDLz14spdDWJxcj1lInVx5ViM7mtW3Nyta7FZykKccevnJir_10jFUriVf-nfPxcXZ7NeXeRS6KkSOtr6PLKYZuALAxXkRx6ByTJ1pSA9BhUlSFTZVjbbck7pAQMxybRKD7F_joD6tX4gD33p8KWQVO60NZI1xRG6jqlwBIGgNCThaaSI-bPe1dKHkOHe-uCzJ9GAylESGksnAPvB0It7vhq_HWhv7Bqo7RCrHt200wr5JJ1tKluGcduVfVE3E291nOmG8g-Cx3dAYLoGWa63iiTgeEbD7PWKPljXoV_9f_LV4MIKNAwdPxEF_vcE3pMz01emA2FNx-Hm2-PGTnrP5-eL7Hz-y93I |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaq9gAIVeVVFgoYCTgRbWLneagqBJQtfZxaaW9h4kyklVpnabKC_VP8xs7EyUIPy63HyI5jeb7Mw_MS4l2sTUqaQOBVQWK8EKPQgwJKYoYYKiD5nMacO3x6Fk8uwu_TaLoh_gy5MBxWOfDEjlGXteE78jFJ_iAhxKngYP7T465R7F0dWmg4WBzj8heZbM3-0Rei73ulDr-ef554fVcBz9CnWy_FMAKTARg_yXwfVIKhiSuSw6gwCIosDVWlU-7JnCEgRomOgxjZv8RBbXwBSix_iwSvz8ZeMl0ZeJxz2idgai9K08zV9FS08bG1VwTIIO2yuG_JwIeueEgv8NYrup3AO9wR272mKj85aD0SG2gfiwf_1C98IppveGVmLZB1jbLES47xwFIWS1ktTD0rwY7ZTVE3YKUFS_Z5H4Yn5y7rqZEzy2prQ2-19e8ZLbaUHFQqu96BsuCxVhqG5rVkJ0PzVFzcyXk_E5u2tvhcyMI3WscQVbEheMWqSBQAgtYQgKGVRuLjcK656Uucc6eNy5xMHSZDTmTImQzscw9H4sNq-tzV9lg3Ud0iUu6ehuiHdS_tDZTMe77Q5H9RPBJvV8P0R_MJgsV6QXO45FqitfJHYtchYLU9Yscpa-wv_r_4G3Fvcn56kp8cnR2_FPcd8DhocU9sttcLfEWKVFu87tArxY-7_l1uAF0oMFU |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB5VqYRACPEmUGCRgBNW7F2_ckAIaENLIaoQlXpzx-uxFKldh9oR5K_x65iJ7UAP4dajtevVeufbeXheAC9jY1PWBAKvDBLrhRSFHuZYMDOkUCPL5zSW3OGv03j_OPx8Ep1swe8-F0bCKnueuGLURWXlH_mIJX-QMOJ0MCq7sIij3cm7-Q9POkiJp7Vvp9FC5JCWP9l8q98e7DKtX2k92fv-cd_rOgx4lrfReCmFEdoxovWTse-jTii0cckymTQFQT5OQ12aVPozjwmJosTEQUzia5IAN_kZyux_OxGraADbH_amR996OSAZqF06pvGiNB23FT41f8bIuXOGZ5CucrovScSbbSmRTvxtVntX4m9yG251eqt63wLtDmyRuws3_qlmeA_qT3RuZw2yrU2qoDOJ-KBC5UtVLmw1K9CNxGlR1eiUQ8fWeheUp-ZtDlStZk6U2JrfaqpfM15sqSTEVK06CapcxhplBagXSlwO9X04vpITfwADVzl6BCr3rTExRmVsGWyxzhONSGgMBmh5pSG86c81s13Bc-m7cZax4SNkyJgMmZBBPPDhEF6vp8_bSh-bJupLRMrapz4WYtNLOz0ls45L1NlfTA_hxXqY77ecIDqqFjxHCrAlxmh_CA9bBKy3x8w5Ff398f8Xfw7X-KpkXw6mh0_geos7iWDcgUFzsaCnrFU1-bMOvgpOr_rG_AGhuTXw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gemcitabine+Delivered+by+Fucoidan%2FChitosan+Nanoparticles+Presents+Increased+Toxicity+Over+Human+Breast+Cancer+Cells&rft.jtitle=Nanomedicine+%28London%2C+England%29&rft.au=Oliveira%2C+Catarina&rft.au=Neves%2C+Nuno+M&rft.au=Reis%2C+Rui+L&rft.au=Martins%2C+Albino&rft.date=2018-08-01&rft.issn=1743-5889&rft.eissn=1748-6963&rft.volume=13&rft.issue=16&rft.spage=2037&rft.epage=2050&rft_id=info:doi/10.2217%2Fnnm-2018-0004&rft.externalDBID=n%2Fa&rft.externalDocID=10_2217_nnm_2018_0004 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1743-5889&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1743-5889&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1743-5889&client=summon |